YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessment

The US$10 promotional assessment organizes self-reported risk factors but does not diagnose cancer or estimate the probability of developing it.

Rhea-AI Summary

YD Bio (Nasdaq: YDES) and EG BioMed launched an online AI cancer risk assessment covering ten cancer types at US$10 promotional pricing. Available in English and Chinese, it uses a 52-question survey of self-reported health information to generate personalized risk-factor reports. The regular price is US$50.

The assessment sits upstream of the companies' laboratory and clinical services. Reports may reference related blood tests for discussion with a physician, who decides whether testing is appropriate. The output does not represent the probability of developing cancer and is not intended for diagnosis, screening, early detection or treatment decisions.

YD Bio entered a memorandum of understanding to merge with EG BioMed in January 2026. The company anticipates closing in 2026, subject to regulatory approvals and finalizing definitive agreements.

2 points · 0 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate point. Forward-looking: it has not happened yet and may not happen.YD Bio anticipates its planned EG BioMed merger will close in 2026.
• Minor pointOnline assessment launched with EG BioMed at US$10 promotional pricing, versus the regular US$50 price.

Negative

• Moderate pointEG BioMed merger remains at memorandum-of-understanding stage, pending regulatory approvals and definitive agreements.
• Minor pointAssessment output does not estimate cancer probability and is not intended for diagnosis, screening or early detection.

Key Figures

Cancer types covered: 10 cancer types Promotional price: US$10 Regular price: US$50 +1 more

Cancer types covered

10 cancer types

AI Cancer Risk Assessment

Promotional price

US$10

Assessment promotional period

Regular price

US$50

Assessment price outside promotional period

Survey questions

52 questions

Assessment health survey

Key Terms

dna methylation, laboratory-developed tests, clia-certified, cap-accredited, +1 more

5 terms

dna methylation medical

"offering DNA methylation–based oncology tests as laboratory-developed tests"

A chemical tag added to DNA that acts like a sticky note on a recipe, changing whether a gene is read without altering the underlying genetic code. For investors, DNA methylation matters because these tags can serve as measurable biomarkers for disease diagnosis, risk prediction, and treatment response, and they can be targets for drugs or diagnostic tests—factors that influence clinical value, regulatory approval, and market potential.

laboratory-developed tests regulatory

"offering DNA methylation–based oncology tests as laboratory-developed tests"

Laboratory-developed tests are medical tests that a single clinical laboratory designs, builds and runs internally rather than buying from outside manufacturers. Think of them as an in-house recipe a lab creates to detect a disease or measure a biomarker; they matter to investors because they can drive revenue, offer faster product development and carry distinct regulatory and reimbursement risks that affect a healthcare company's financial outlook.

clia-certified regulatory

"operates a CLIA-certified and CAP-accredited laboratory in Bothell, Washington"

CLIA-certified means a laboratory has passed U.S. federal standards for performing tests on human samples, showing its results are accurate, reliable and timely. For investors this matters because certification is often required to sell clinical test services, bill insurers, win hospital or physician partnerships and avoid regulatory penalties — much like a restaurant passing a health inspection or a car getting a safety sticker before it can be sold.

cap-accredited regulatory

"operates a CLIA-certified and CAP-accredited laboratory in Bothell, Washington"

Cap-accredited means a laboratory or diagnostic service has been inspected and certified by the College of American Pathologists (CAP) for meeting rigorous standards in testing accuracy, quality control, staff qualifications and reporting. For investors, CAP accreditation signals that the lab’s results are more reliable and that the operation meets a well-recognized regulatory benchmark, which can reduce clinical and regulatory risk and support market trust and reimbursement; think of it like a high-score health inspection for a restaurant.

age-standardized incidence rates medical

"using age-standardized incidence rates"

The number of new cases of a disease or condition per unit of population after removing the effect of different age distributions, so rates from different populations or times can be compared. It is calculated by applying the observed age-specific incidence rates to a single standard age structure (direct standardization) or by comparing observed to expected cases based on that standard (indirect standardization); the resulting figure represents what the incidence would be if the population had the standard age mix. Choosing a particular standard population and the method (direct versus indirect) affects the value, so age-standardized rates are comparable only when the same standard and method are used.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TAIPEI, Taiwan, and BOTHELL, Wash., Oct. 06, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the Company and EG BioMed Co., Ltd., a Taiwan registered company (“EG BioMed”), officially launched the AI Cancer Risk Assessment (the “Assessment”), an online assessment that organizes an individual's self-reported health information into a personalized report in English and Chinese, covering ten cancer types with promotional pricing of US$10.

The Assessment is based on a 52-question health survey covering personal and family history, symptoms, lifestyle, environmental exposures and diet. The survey takes approximately ten minutes, with a personalized report generated shortly after completion. The report provides low, moderate or high risk stratification overall and for each of ten cancer types: breast, colorectal, lung, head and neck, pancreatic, liver, endometrial, prostate, biliary tract and gastric cancer. It identifies the factors that contributed most to each result, explains why they may be relevant, and includes screening information and personalized follow-up guidance. The Assessment requires no blood draw, imaging or a clinic visit.

Assessment Methodology and Report

Responses are processed by a 48-feature pan-cancer model and ten cancer-specific models, together with a separate rule layer built from published clinical literature. This rule layer draws on more than 140 primary research studies and over 300 traceable risk estimates, with each rule tied to a source study and reported measure. The report includes the rules triggered by the user's responses, their bases and references to the underlying medical literature.

Results are presented against the population baseline of the country the respondent selects, using age-standardized incidence rates. The accompanying screening information also reflects guidance issued by a particular country, as applicable (currently, the United States, Canada and Taiwan). Where a country has no national recommendation for a given cancer, the report says so rather than substituting another country's advice.

Integration with the Companies' Oncology Services

The Assessment sits upstream of the companies' laboratory and clinical services. EG BioMed US Inc. (“EG BioMed US”) operates a CLIA-certified and CAP-accredited laboratory in Bothell, Washington, offering DNA methylation–based oncology tests as laboratory-developed tests. Its operational footprint spans 47 U.S. states, Washington, D.C., Guam, the U.S. Virgin Islands and American Samoa. In March 2026, YD Bio and EG BioMed launched a nationwide telehealth platform to support decentralized access to such services.

For individuals whose Assessment indicates a denser cluster of risk factors associated with certain cancer types, the report may reference the availability of related blood tests for discussion with a physician. Whether any test is appropriate remains a decision for a licensed physician.

“Understanding personal health risk factors can be a useful starting point for more informed discussions with healthcare professionals,” said Dr. Ethan Shen, Founder, Chairman and Chief Executive Officer of YD Bio. “This Assessment brings self-reported health information and published research together in a structured, personalized report. As part of our broader oncology platform, we believe it can help individuals better understand their risk factors and discuss appropriate next steps with their physicians.”

The AI Cancer Risk Assessment is available now in English and Chinese at mdi.eg-bio.com/product/ai-cancer-risk-assessment. During the promotional period, the Assessment is offered at US$10, reduced from its regular price of US$50.

Important Disclosure about the Assessment

The AI Cancer Risk Assessment is a cancer risk-stratification and health guidance tool. It uses statistical and artificial intelligence methods applied to health information self-reported by the user. Its output does not represent the probability of developing cancer. It does not diagnose cancer and is not intended for cancer diagnosis, screening, early detection, disease prediction or treatment decision-making; it cannot replace professional medical evaluation, diagnostic testing or consultation with a qualified healthcare provider.

About EG BioMed

EG BioMed is a biotechnology and clinical services company focused on advancing early cancer detection and diagnostic solutions. YD Bio entered into a Memorandum of Understanding to merge with EG BioMed in January 2026 and is advancing the transaction, which is anticipated to close in 2026, subject to customary closing conditions, regulatory approvals, and the finalization of definitive agreements.

EG BioMed US is the U.S. clinical-laboratory subsidiary of EG BioMed and operates a CLIA-certified, CAP-accredited clinical laboratory in Bothell, Washington, focused on DNA methylation–based early cancer detection and AI-driven biomarker analytics. EG BioMed and EG BioMed US are affiliates of YD Bio.

About YD Bio Limited

YD Bio is a U.S.-anchored public biotechnology company building an integrated healthcare platform spanning regulated molecular diagnostics, clinical services, precision medicine, and life science commercialization. The Company operates DNA methylation–based oncology testing programs in the United States under a laboratory-developed test strategy and supports pharmaceutical and biotechnology partners through compliant life science distribution and clinical trial supply chain services. In addition, the Company maintains regulated ocular health commercialization operations and a consumer health distribution platform in Asia. For more information, visit ir.ydesgroup.com and follow the Company on Facebook, X, Threads, Instagram and LinkedIn.

Forward-looking statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions created by the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s plans, objectives and expectations for its business, strategy, operations, and certain on-going transactions, and the potential benefit of the Assessment and any synergies with its other oncology services. Forward-looking statements are not guarantees of future performance and can be identified by words such as “aim,” “intend,” “seek,” “believe,” “designed to,” “expects,” “anticipates,” “plans,” “may,” “could,” “will” and other similar expressions. Actual results may differ materially from those expressed or implied due to a variety of factors, including consumer demand and market acceptance; competition; regulatory and labeling requirements in Taiwan and other jurisdictions; currency exchange rates; geopolitical tensions and macroeconomic conditions; and other risks and uncertainties described in YD Bio’s filings with the U.S. Securities and Exchange Commission. The Company cautions investors not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update any forward-looking statement, except as required by law, and encourages investors to review the risk factors in its Annual Report on Form 20-F and other SEC filings.

For investor and media inquiries, please contact:
YD Bio Limited
Investor Relations
Email: investor@ydesgroup.com

WFS Investor Relations Inc.
Email: services@wfsir.com
Phone: +1 628 283 9214

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much does YD Bio and EG BioMed's AI cancer risk assessment cost?

The assessment costs US$10 during the promotional period, reduced from its regular price of US$50. It is available now in English and Chinese.

Can YD Bio's AI cancer risk assessment diagnose cancer?

No, the assessment does not diagnose cancer or represent the probability of developing it. It organizes self-reported health information into risk-factor reports and cannot replace professional medical evaluation, diagnostic testing or consultation with a qualified healthcare provider.

How does YD Bio's AI cancer risk assessment handle country-specific screening guidance?

The report uses the selected country's population baseline and applicable country-specific screening guidance, currently covering the United States, Canada and Taiwan. Where a country has no national recommendation for a cancer type, the report identifies that absence rather than substituting another country's advice.

How long does YD Bio's AI cancer risk assessment take, and does it require a clinic visit?

The survey takes approximately ten minutes, with a personalized report generated shortly after completion. It requires no blood draw, imaging or clinic visit.